Cargando…

Establishment of a 3D In Vitro Model to Accelerate the Development of Human Therapies against Corneal Diabetes

PURPOSE: To establish an in vitro model that would mirror the in vivo corneal stromal environment in diabetes (DM) patients. METHODS: Human corneal fibroblasts from Healthy (HCFs), Type 1DM (T1DM) and Type 2DM (T2DM) donors were isolated and cultured for 4 weeks with Vitamin C stimulation in order t...

Descripción completa

Detalles Bibliográficos
Autores principales: Priyadarsini, Shrestha, Sarker-Nag, Akhee, Rowsey, Tyler G., Ma, Jian-Xing, Karamichos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179241/
https://www.ncbi.nlm.nih.gov/pubmed/28005998
http://dx.doi.org/10.1371/journal.pone.0168845
_version_ 1782485336545296384
author Priyadarsini, Shrestha
Sarker-Nag, Akhee
Rowsey, Tyler G.
Ma, Jian-Xing
Karamichos, Dimitrios
author_facet Priyadarsini, Shrestha
Sarker-Nag, Akhee
Rowsey, Tyler G.
Ma, Jian-Xing
Karamichos, Dimitrios
author_sort Priyadarsini, Shrestha
collection PubMed
description PURPOSE: To establish an in vitro model that would mirror the in vivo corneal stromal environment in diabetes (DM) patients. METHODS: Human corneal fibroblasts from Healthy (HCFs), Type 1DM (T1DM) and Type 2DM (T2DM) donors were isolated and cultured for 4 weeks with Vitamin C stimulation in order to allow for extracellular matrix (ECM) secretion and assembly. RESULTS: Our data indicated altered cellular morphology, increased cellular migration, increased ECM assembly, and severe mitochondrial damage in both T1DM and T2DMs when compared to HCFs. Furthermore, we found significant downregulation of Collagen I and Collagen V expression in both T1DM and T2DMs. Furthermore, a significant up regulation of fibrotic markers was seen, including α-smooth muscle actin in T2DM and Collagen III in both T1DM and T2DMs. Metabolic analysis suggested impaired Glycolysis and Tricarboxylic acid cycle (TCA) pathway. CONCLUSION: DM has significant effects on physiological and clinical aspects of the human cornea. The benefits in developing and fully characterizing our 3D in vitro model are enormous and might provide clues for the development of novel therapeutics.
format Online
Article
Text
id pubmed-5179241
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-51792412017-01-04 Establishment of a 3D In Vitro Model to Accelerate the Development of Human Therapies against Corneal Diabetes Priyadarsini, Shrestha Sarker-Nag, Akhee Rowsey, Tyler G. Ma, Jian-Xing Karamichos, Dimitrios PLoS One Research Article PURPOSE: To establish an in vitro model that would mirror the in vivo corneal stromal environment in diabetes (DM) patients. METHODS: Human corneal fibroblasts from Healthy (HCFs), Type 1DM (T1DM) and Type 2DM (T2DM) donors were isolated and cultured for 4 weeks with Vitamin C stimulation in order to allow for extracellular matrix (ECM) secretion and assembly. RESULTS: Our data indicated altered cellular morphology, increased cellular migration, increased ECM assembly, and severe mitochondrial damage in both T1DM and T2DMs when compared to HCFs. Furthermore, we found significant downregulation of Collagen I and Collagen V expression in both T1DM and T2DMs. Furthermore, a significant up regulation of fibrotic markers was seen, including α-smooth muscle actin in T2DM and Collagen III in both T1DM and T2DMs. Metabolic analysis suggested impaired Glycolysis and Tricarboxylic acid cycle (TCA) pathway. CONCLUSION: DM has significant effects on physiological and clinical aspects of the human cornea. The benefits in developing and fully characterizing our 3D in vitro model are enormous and might provide clues for the development of novel therapeutics. Public Library of Science 2016-12-22 /pmc/articles/PMC5179241/ /pubmed/28005998 http://dx.doi.org/10.1371/journal.pone.0168845 Text en © 2016 Priyadarsini et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Priyadarsini, Shrestha
Sarker-Nag, Akhee
Rowsey, Tyler G.
Ma, Jian-Xing
Karamichos, Dimitrios
Establishment of a 3D In Vitro Model to Accelerate the Development of Human Therapies against Corneal Diabetes
title Establishment of a 3D In Vitro Model to Accelerate the Development of Human Therapies against Corneal Diabetes
title_full Establishment of a 3D In Vitro Model to Accelerate the Development of Human Therapies against Corneal Diabetes
title_fullStr Establishment of a 3D In Vitro Model to Accelerate the Development of Human Therapies against Corneal Diabetes
title_full_unstemmed Establishment of a 3D In Vitro Model to Accelerate the Development of Human Therapies against Corneal Diabetes
title_short Establishment of a 3D In Vitro Model to Accelerate the Development of Human Therapies against Corneal Diabetes
title_sort establishment of a 3d in vitro model to accelerate the development of human therapies against corneal diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179241/
https://www.ncbi.nlm.nih.gov/pubmed/28005998
http://dx.doi.org/10.1371/journal.pone.0168845
work_keys_str_mv AT priyadarsinishrestha establishmentofa3dinvitromodeltoacceleratethedevelopmentofhumantherapiesagainstcornealdiabetes
AT sarkernagakhee establishmentofa3dinvitromodeltoacceleratethedevelopmentofhumantherapiesagainstcornealdiabetes
AT rowseytylerg establishmentofa3dinvitromodeltoacceleratethedevelopmentofhumantherapiesagainstcornealdiabetes
AT majianxing establishmentofa3dinvitromodeltoacceleratethedevelopmentofhumantherapiesagainstcornealdiabetes
AT karamichosdimitrios establishmentofa3dinvitromodeltoacceleratethedevelopmentofhumantherapiesagainstcornealdiabetes